IV infusions by treatment group
| . | Median (IQR) . | P . | |
|---|---|---|---|
| Platelets (n = 137) . | No platelets (n = 124) . | ||
| Prerandomized products, units | |||
| RBCs | 2 (1-3) | 2 (1-2) | .26 |
| Plasma | 0 (0-1) | 0 (0-0) | .40 |
| Platelets | 0 (0-0) | 0 (0-0) | .35 |
| Cryoprecipitate | 0 (0-0) | 0 (0-0) | 1.00 |
| Colloids | 0 (0-0) | 0 (0-0) | .37 |
| Crystalloids, L | 1.75 (1.0-3.0) | 1.35 (0.40-2.73) | .07 |
| Randomized products, units | |||
| RBCs | 3 (2-4) | 3 (2-4) | .06 |
| Plasma | 2 (1-3) | 1 (0-2) | <.01 |
| Platelets | 6 (6-6) | 0 (0-0) | <.01 |
| Time from randomization to platelet infusion, min | 2 (1-5) | NA | |
| Total product from prehospital to first 24 h, units | |||
| RBCs | 5 (3-7) | 5 (4-7) | .64 |
| Plasma | 3 (2-5) | 2 (1-3) | <.01 |
| Platelets | 6 (6-6) | 0 (0-0) | <.01 |
| Cryoprecipitate | 0 (0-0) | 0 (0-0) | .44 |
| Colloids | 0 (0-0.25) | 0 (0-0) | .10 |
| Crystalloids, L | 6.30 (3.95-8.70) | 5.00 (2.45-8.88) | .13 |
| . | Median (IQR) . | P . | |
|---|---|---|---|
| Platelets (n = 137) . | No platelets (n = 124) . | ||
| Prerandomized products, units | |||
| RBCs | 2 (1-3) | 2 (1-2) | .26 |
| Plasma | 0 (0-1) | 0 (0-0) | .40 |
| Platelets | 0 (0-0) | 0 (0-0) | .35 |
| Cryoprecipitate | 0 (0-0) | 0 (0-0) | 1.00 |
| Colloids | 0 (0-0) | 0 (0-0) | .37 |
| Crystalloids, L | 1.75 (1.0-3.0) | 1.35 (0.40-2.73) | .07 |
| Randomized products, units | |||
| RBCs | 3 (2-4) | 3 (2-4) | .06 |
| Plasma | 2 (1-3) | 1 (0-2) | <.01 |
| Platelets | 6 (6-6) | 0 (0-0) | <.01 |
| Time from randomization to platelet infusion, min | 2 (1-5) | NA | |
| Total product from prehospital to first 24 h, units | |||
| RBCs | 5 (3-7) | 5 (4-7) | .64 |
| Plasma | 3 (2-5) | 2 (1-3) | <.01 |
| Platelets | 6 (6-6) | 0 (0-0) | <.01 |
| Cryoprecipitate | 0 (0-0) | 0 (0-0) | .44 |
| Colloids | 0 (0-0.25) | 0 (0-0) | .10 |
| Crystalloids, L | 6.30 (3.95-8.70) | 5.00 (2.45-8.88) | .13 |
Comparison of continuous variable between 2 groups was evaluated by the Wilcoxon rank sum test. Total blood products include all prehospital, prerandomized, randomized, and postrandomized products up to 24 hours after admission. No postrandomized platelets were administered in either group.
NA, not applicable.